Common Ground: Both studies explore multi-targeted strategies for treating neurodegenerative diseases with a focus on crossing the blood-brain barrier (BBB) and cholingeric enzyme inhibition.
Key Differences: The current study assesses the effects of a quercetin-THIQ derivative on AChE/BuChE inhibition and its lipophilicity. The recommended study evaluates multiple N-methylpropargylamino-quinazoline derivatives for cholinesterases, MAO-B inhibition, and NMDAR antagonism.
Methodologies: The current study uses a Mannich reaction for synthesis and in vitro enzyme inhibition analysis. The recommended study employs in silico screening, in vitro enzyme assays, and cytotoxicity tests on neuroblastoma cells.
Complementary Aspects: The current study contributes to understanding BuChE selectivity and lipophilicity enhancement. The recommended study broadens the scope by integrating multi-target activity including MAO-B inhibition and NMDAR antagonism.
Potential Impact: Combining the findings could lead to multi-target drugs with improved bioavailability and therapeutic efficacy for neurodegenerative diseases.

Scheduled maintenance in progress.